Masimo Corporation (MASI)
NASDAQ: MASI · IEX Real-Time Price · USD
134.41
-1.79 (-1.31%)
At close: Apr 30, 2024, 4:00 PM
135.00
+0.59 (0.44%)
Pre-market: May 1, 2024, 7:03 AM EDT
Masimo Revenue
In the year 2023, Masimo had annual revenue of $2.05B with 0.60% growth. Revenue in the quarter ending December 30, 2023 was $548.90M, a -11.04% decrease year-over-year.
Revenue (ttm)
$2.05B
Revenue Growth
+0.60%
P/S Ratio
3.47
Revenue / Employee
$538,974
Employees
3,800
Market Cap
7.11B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 30, 2023 | 2.05B | 12.30M | 0.60% |
Dec 31, 2022 | 2.04B | 892.10M | 78.00% |
Jan 1, 2022 | 1.14B | -44.00K | -0.00% |
Jan 2, 2021 | 1.14B | 205.91M | 21.96% |
Dec 28, 2019 | 937.84M | - | - |
Dec 29, 2018 | 937.84M | 79.55M | 9.27% |
Dec 30, 2017 | 858.29M | 145.39M | 20.39% |
Dec 31, 2016 | 712.90M | 82.79M | 13.14% |
Jan 2, 2016 | 630.11M | 43.47M | 7.41% |
Jan 3, 2015 | 586.64M | 39.40M | 7.20% |
Dec 28, 2013 | 547.25M | 54.01M | 10.95% |
Dec 29, 2012 | 493.23M | 54.25M | 12.36% |
Dec 31, 2011 | 438.99M | 33.58M | 8.28% |
Jan 1, 2011 | 405.41M | 56.29M | 16.12% |
Jan 2, 2010 | 349.12M | 42.04M | 13.69% |
Jan 3, 2009 | 307.07M | 50.79M | 19.82% |
Dec 29, 2007 | 256.29M | 31.95M | 14.24% |
Dec 31, 2006 | 224.34M | 116.45M | 107.93% |
Dec 31, 2005 | 107.89M | 38.53M | 55.56% |
Dec 31, 2004 | 69.36M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Bio-Rad Laboratories | 2.67B |
Exelixis | 1.83B |
Globus Medical | 1.57B |
Penumbra | 1.06B |
HealthEquity | 999.59M |
Inspire Medical Systems | 624.80M |
Intra-Cellular Therapies | 464.37M |
Ascendis Pharma | 296.35M |
MASI News
- 8 days ago - Masimo to Report First Quarter 2024 Financial Results after Market Close on Tuesday, May 7 - Business Wire
- 15 days ago - Masimo Founder and CEO Joe Kiani to Speak on AI at Global Patient Safety Summit in Chile - Business Wire
- 20 days ago - Masimo To Explore Spin-Off Of Its Consumer Unit - Forbes
- 4 weeks ago - Masimo Responds to Politan Capital's Nomination of Director Candidates and Refutes Politan's False Claims - Business Wire
- 5 weeks ago - Masimo May Look at Joint Venture for Consumer Split, CEO Says - WSJ
- 5 weeks ago - Activist investor plans second fight at Masimo, sending shares up 12% - CNBC
- 5 weeks ago - Politan Nominates Two Independent Candidates for Masimo Board - Business Wire
- 5 weeks ago - Masimo's stock rallies on report of looming activist campaign, disclosure of spinoff plan - Market Watch